1209 related articles for article (PubMed ID: 34744510)
41. The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab.
Liu J; Gao D; Li J; Hu G; Liu J; Liu D
Onco Targets Ther; 2022; 15():1161-1170. PubMed ID: 36238132
[TBL] [Abstract][Full Text] [Related]
42. Preoperative Systemic Immune-Inflammation Index (SII) as a Superior Predictor of Long-Term Survival Outcome in Patients With Stage I-II Gastric Cancer After Radical Surgery.
He K; Si L; Pan X; Sun L; Wang Y; Lu J; Wang X
Front Oncol; 2022; 12():829689. PubMed ID: 35296020
[TBL] [Abstract][Full Text] [Related]
43. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.
Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W
BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843
[TBL] [Abstract][Full Text] [Related]
44. Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer.
Inoue H; Kosuga T; Kubota T; Konishi H; Shiozaki A; Okamoto K; Fujiwara H; Otsuji E
World J Surg Oncol; 2021 Jun; 19(1):173. PubMed ID: 34118953
[TBL] [Abstract][Full Text] [Related]
45. Systemic Immune-inflammation Index Predicts Survival of Patients After Curative Resection for Non-small Cell Lung Cancer.
Tomita M; Ayabe T; Maeda R; Nakamura K
In Vivo; 2018; 32(3):663-667. PubMed ID: 29695576
[TBL] [Abstract][Full Text] [Related]
46. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
47. The Relationship Between Preoperative Systemic Immune Inflammation Index and Prognostic Nutritional Index and the Prognosis of Patients With Alveolar Hydatid Disease.
Ren B; Chen X; Lei P; Hou L; Wang H; Zhou Y; Ren L; Fan H; Wang Z; Yuan J
Front Immunol; 2021; 12():691364. PubMed ID: 34248983
[TBL] [Abstract][Full Text] [Related]
48. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
49. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
[TBL] [Abstract][Full Text] [Related]
50. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.
Şahin E; Kefeli U; Zorlu Ş; Seyyar M; Ozkorkmaz Akdag M; Can Sanci P; Karakayali A; Ucuncu Kefeli A; Bakkal Temi Y; Cabuk D; Uygun K
Medicine (Baltimore); 2023 Nov; 102(47):e35843. PubMed ID: 38013293
[TBL] [Abstract][Full Text] [Related]
51. Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer.
Keit E; Coutu B; Zhen W; Zhang C; Lin C; Bennion N; Ganti AK; Ernani V; Baine M
Ann Transl Med; 2021 Feb; 9(3):227. PubMed ID: 33708854
[TBL] [Abstract][Full Text] [Related]
52. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.
Lolli C; Caffo O; Scarpi E; Aieta M; Conteduca V; Maines F; Bianchi E; Massari F; Veccia A; Chiuri VE; Facchini G; De Giorgi U
Front Pharmacol; 2016; 7():376. PubMed ID: 27790145
[No Abstract] [Full Text] [Related]
53. Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model.
Duan X; Yang B; Zhao C; Tie B; Cao L; Gao Y
BMC Cancer; 2023 May; 23(1):432. PubMed ID: 37173662
[TBL] [Abstract][Full Text] [Related]
54. The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.
Yang H; Wang K; Li B; Li S; Li Y; Yuan L
Front Oncol; 2021; 11():707041. PubMed ID: 34917497
[TBL] [Abstract][Full Text] [Related]
55. Prognostic nutritional index and systemic immune-inflammation index are prognostic biomarkers for non-small-cell lung cancer brain metastases.
Li W; Qu Y; Wen F; Yu R; He X; Jia H; Liu H; Yu H
Biomark Med; 2021 Sep; 15(13):1071-1084. PubMed ID: 34397267
[No Abstract] [Full Text] [Related]
56. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
[No Abstract] [Full Text] [Related]
57. The pretherapeutic systemic inflammation score is a prognostic predictor for elderly patients with oesophageal cancer: a case control study.
Huang C; Wang M; Chen L; Wang H; Huang D; Shi J; Zhang W; Tian Y; Zhu Y
BMC Cancer; 2023 Jun; 23(1):505. PubMed ID: 37270496
[TBL] [Abstract][Full Text] [Related]
58. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy.
Chen L; Yan Y; Zhu L; Cong X; Li S; Song S; Song H; Xue Y
Cancer Manag Res; 2017; 9():849-867. PubMed ID: 29276407
[TBL] [Abstract][Full Text] [Related]
59. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma.
Gao Y; Guo W; Cai S; Zhang F; Shao F; Zhang G; Liu T; Tan F; Li N; Xue Q; Gao S; He J
J Cancer; 2019; 10(14):3188-3196. PubMed ID: 31289589
[No Abstract] [Full Text] [Related]
60. Prognostic Value of Inflammatory Markers in Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era.
Li Q; Yu L; Yang P; Hu Q
Cancer Manag Res; 2021; 13():6799-6810. PubMed ID: 34512020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
